Arrowhead Pharmaceuticals has celebrated Rare Disease Day with the expansion of the We’ll Get There Soon campaign, initially launched for healthcare providers in November 2024.

This new phase introduces a dedicated educational website, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).

FCS is an ultra-rare genetic disorder that significantly impairs the body's ability to process triglycerides, leading to dangerously high triglyceride (TG) levels — typically exceeding 880 mg/dL — and increasing the risk of life-threatening complications, such as acute pancreatitis.

Because of this risk, expert guidelines recommend maintaining triglyceride levels below 500 mg/dL. FCS remains widely underdiagnosed and is estimated to affect between 1 and 13 people per million globally. To address this gap, Arrowhead’s new initiatives aim to amplify patient voices, foster community, and provide accessible educational tools.

Arrowhead’s new patient website serves as a comprehensive resource for those affected by FCS and extremely high triglycerides. It provides educational content, patient testimonials, and opportunities for community connection.

Additionally, the Spotlight on FCS white paper, developed with engagement and support of the FCS Foundation, Action FCS, and FH Europe Foundation, captures firsthand patient experiences, highlighting key challenges in disease management and aiming to drive greater awareness and action.

“In recognition of Rare Disease Day, we prioritize giving the FCS community a voice. Arrowhead’s Spotlight on FCS white paper, which highlights what life looks like for those living with this ultra-rare condition, is a novel look at how these individuals are navigating life with FCS,” said Lindsey Sutton, Co-Founder of FCS Foundation.

“This paper is a major contribution to the community as it sheds a light on the unmet needs patients face with their disease from their firsthand experiences,” added Sutton.

Andy Davis, Senior Vice President, Global Cardiometabolic Franchise at Arrowhead, added, “For nearly two decades, Arrowhead has been dedicated to advancing RNAi-based therapies to address challenging diseases. These new resources reaffirm our commitment to the FCS community by enhancing awareness, support, and access to information through the expansion of the We’ll Get There Soon campaign.”